DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of DBV Technologies in a report on Thursday, July 6th. Deutsche Bank AG initiated coverage on shares of DBV Technologies in a report on Friday, June 23rd. They set a “buy” rating and a $46.00 price target for the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of DBV Technologies in a report on Thursday, June 1st. Zacks Investment Research raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Monday, April 24th. Finally, ValuEngine raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. DBV Technologies has an average rating of “Buy” and a consensus target price of $48.83.

DBV Technologies (NASDAQ:DBVT) traded up 0.05% during midday trading on Friday, hitting $43.20. 97,258 shares of the company traded hands. The company’s market capitalization is $1.99 billion. DBV Technologies has a 12-month low of $31.87 and a 12-month high of $46.33. The stock’s 50-day moving average price is $40.99 and its 200 day moving average price is $36.16.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/13/dbv-technologies-s-a-dbvt-downgraded-by-bidaskclub-to-hold.html.

A number of institutional investors have recently modified their holdings of DBVT. Victory Capital Management Inc. bought a new position in shares of DBV Technologies during the first quarter valued at approximately $303,000. Airain ltd bought a new position in shares of DBV Technologies during the second quarter valued at approximately $333,000. DekaBank Deutsche Girozentrale bought a new position in shares of DBV Technologies during the first quarter valued at approximately $471,000. Simplex Trading LLC bought a new position in shares of DBV Technologies during the first quarter valued at approximately $526,000. Finally, Sit Investment Associates Inc. bought a new position in shares of DBV Technologies during the second quarter valued at approximately $698,000. 47.98% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.